SAN FRANCISCO (AP) _ FibroGen Inc. (FGEN) on Wednesday reported a loss of $34 million in its fourth quarter.
On a per-share basis, the San Francisco-based company said it had a loss of 54 cents.
The results beat Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 65 cents per share.
The biotech drug developer posted revenue of $31.9 million in the period, also exceeding Street forecasts. Three analysts surveyed by Zacks expected $19.3 million.
For the year, the company reported that its loss narrowed to $61.7 million, or 98 cents per share. Revenue was reported as $179.6 million.
FibroGen shares have climbed 20 percent since the beginning of the year. In the final minutes of trading on Wednesday, shares hit $25.65, an increase of 42 percent in the last 12 months.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on FGEN at https://www.zacks.com/ap/FGEN
Keywords: FibroGen, Earnings Report